BrainNeurosciencePeer-reviewed journal article
Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia
Laura PasettoiD, Maurizio GrassanoiD, Silvia PozziiD, Silvia Luotti, Eliana Sammali, Alice MigazziiD, Manuela BassoiD, Giovanni SpagnolliiD, Emiliano BiasiniiD, Edoardo MicottiiD, Milica CeroviciD, Mirjana CarliiD, Gianluigi ForloniiD, Giovanni De MarcoiD, Umberto ManeraiD, Cristina MogliaiD, Gabriele MoraiD, Bryan J. TraynoriD, Adriano ChiòiD, Andrea CalvoiD, Valentina BonettoiD
Abstract
Aggregation and cytoplasmic mislocalization of TDP-43 are pathological hallmarks of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) spectrum. However, the molecular mechanism by which TDP-43 aggregates form and cause neurodegeneration remains poorly understood. Cyclophilin A, also known as peptidyl-prolyl cis-trans isomerase A (PPIA), is a foldase and molecular chaperone. We previously found that PPIA interacts with TDP-43 and governs some of its functions, and its deficiency accelerates disease in a mouse model of ALS. Here we characterized PPIA knock-out mice throughout their lifespan and found that they develop a neurodegenerative disease with key behavioural features of FTD, marked TDP-43 pathology and late-onset motor dysfunction. In the mouse brain, deficient PPIA induces aggregation of the GTP-binding nuclear protein Ran, a PPIA substrate required for TDP-43 nucleocytoplasmic trafficking. Moreover, in absence of PPIA, TDP-43 autoregulation is perturbed and TDP-43 and proteins involved in synaptic function are downregulated, leading to impairment of synaptic plasticity. Finally, we found that PPIA was downregulated in several ALS and ALS-FTD patients and identified a PPIA loss-of-function mutation in a sporadic ALS patient. The mutant PPIA has low stability, altered structure and impaired interaction with TDP-43. These findings strongly implicate that defective PPIA function causes TDP-43 mislocalization and dysfunction and should be considered in future therapeutic approaches.
- organism: mouse
- assay: protein structure
- assay: protein sequence
- research focus: cell type annotation
- research focus: differential expression
- research focus: protein structure prediction
- research focus: protein design
- approach: experimental assay
- Citations
- 32
- FWCI
- 2.63
- Field percentile
- top 8%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A transient protein folding response targets aggregation in the early phase of TDP-43-mediated disease
Rebecca San Gil, Dana Pascovici, … Adam K. Walker·bioRxiv·Jun 21, 2023
- Seeded aggregation of ANXA11 induces prion-like propagation, TDP-43 co-pathology and nucleocytoplasmic transport defects
Haiyang Luo, Honglin Zheng, … Yuming Xu·bioRxiv·Mar 26, 2026
- Mislocalisation of TDP-43 to the cytoplasm of either neurons or oligodendrocytes causes axonopathy and dysmyelination
Marcus Keatinge, Sandra Constantinou Juhasz, … Siddharthan Chandran·bioRxiv·Nov 17, 2025
- TDP-43 expression in the cytoplasm leads to early synaptic and mitochondrial abnormalities in an inducible mouse model of ALS/FTD
Florencia Vassallu, Milagros López, … Lionel Muller Igaz·Neurochemistry InternationalPeer-reviewed·May 13, 2026
- Tauopathy primes co-filament assembly and dysfunction of TDP-43
Meghraj Singh Baghel, Grace D. Burns, … Philip C. Wong·bioRxiv·May 14, 2026
- A Human Neuronal Cell Model of Endogenous TDP-43 A315T Reveals Altered Protein Dynamics and Disease-Relevant Cellular Dysfunction
M.E. Cicardi, Sara Antonini, … Davide Trotti·bioRxiv·Sep 5, 2026